ArticleCurrent oncology (Toronto, Ont.)2022

Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma.

Takashi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.